TY - JOUR
T1 - Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment
T2 - a randomised, controlled trial
AU - Steenholdt, Casper
AU - Brynskov, Jørn
AU - Thomsen, Ole Østergaard
AU - Munck, Lars Kristian
AU - Fallingborg, Jan
AU - Christensen, Lisbet Ambrosius
AU - Pedersen, Gitte
AU - Kjeldsen, Jens Christian William
AU - Jacobsen, Bent Ascanius
AU - Oxholm, Anne Sophie
AU - Kjellberg, Jakob
AU - Bendtzen, Klaus
AU - Ainsworth, Mark Andrew
PY - 2014
Y1 - 2014
N2 - Although the reasons for secondary loss of response to infliximab (IFX) maintenance therapy in Crohn's disease vary, dose intensification is usually recommended. This study investigated the cost-effectiveness of interventions defined by an algorithm designed to identify specific reasons for therapeutic failure.
AB - Although the reasons for secondary loss of response to infliximab (IFX) maintenance therapy in Crohn's disease vary, dose intensification is usually recommended. This study investigated the cost-effectiveness of interventions defined by an algorithm designed to identify specific reasons for therapeutic failure.
U2 - 10.1136/gutjnl-2013-305279
DO - 10.1136/gutjnl-2013-305279
M3 - Journal article
C2 - 23878167
VL - 4
SP - 919
JO - Gut
JF - Gut
SN - 0017-5749
IS - 63
ER -